Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Anemia Drugs Market

ID: MRFR/Pharma/18322-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026

US Anemia Drugs Market Research Report By Anemia Type (Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia, others), By Route of Administration (Oral, Injectable), By Product Type (Biologics, Non-Biologics) and By End User (Hospitals, Self-Administered) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Anemia Drugs Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Medical Device, BY Type (USD Million)
  49.     4.1.1 sickle cell anemia
  50.     4.1.2 plastic anemia
  51.     4.1.3 iron-deficiency anemia
  52.   4.2 Medical Device, BY therapy type (USD Million)
  53.     4.2.1 Oral Iron Therapy
  54.     4.2.2 Red Blood Cell Transfusion
  55.     4.2.3 Parental Iron Therapy
  56.     4.2.4 Other Therapy Types
  57.   4.3 Medical Device, BY end-user (USD Million)
  58.     4.3.1 Clinic
  59.     4.3.2 Healthcare
  60.     4.3.3 Home healthcare
  61. 5 SECTION V: COMPETITIVE ANALYSIS
  62.   5.1 Competitive Landscape
  63.     5.1.1 Overview
  64.     5.1.2 Competitive Analysis
  65.     5.1.3 Market share Analysis
  66.     5.1.4 Major Growth Strategy in the Medical Device
  67.     5.1.5 Competitive Benchmarking
  68.     5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
  69.     5.1.7 Key developments and growth strategies
  70.       5.1.7.1 New Product Launch/Service Deployment
  71.       5.1.7.2 Merger & Acquisitions
  72.       5.1.7.3 Joint Ventures
  73.     5.1.8 Major Players Financial Matrix
  74.       5.1.8.1 Sales and Operating Income
  75.       5.1.8.2 Major Players R&D Expenditure. 2023
  76.   5.2 Company Profiles
  77.     5.2.1 Amgen (US)
  78.       5.2.1.1 Financial Overview
  79.       5.2.1.2 Products Offered
  80.       5.2.1.3 Key Developments
  81.       5.2.1.4 SWOT Analysis
  82.       5.2.1.5 Key Strategies
  83.     5.2.2 Roche (CH)
  84.       5.2.2.1 Financial Overview
  85.       5.2.2.2 Products Offered
  86.       5.2.2.3 Key Developments
  87.       5.2.2.4 SWOT Analysis
  88.       5.2.2.5 Key Strategies
  89.     5.2.3 Novartis (CH)
  90.       5.2.3.1 Financial Overview
  91.       5.2.3.2 Products Offered
  92.       5.2.3.3 Key Developments
  93.       5.2.3.4 SWOT Analysis
  94.       5.2.3.5 Key Strategies
  95.     5.2.4 Bristol-Myers Squibb (US)
  96.       5.2.4.1 Financial Overview
  97.       5.2.4.2 Products Offered
  98.       5.2.4.3 Key Developments
  99.       5.2.4.4 SWOT Analysis
  100.       5.2.4.5 Key Strategies
  101.     5.2.5 Pfizer (US)
  102.       5.2.5.1 Financial Overview
  103.       5.2.5.2 Products Offered
  104.       5.2.5.3 Key Developments
  105.       5.2.5.4 SWOT Analysis
  106.       5.2.5.5 Key Strategies
  107.     5.2.6 Sanofi (FR)
  108.       5.2.6.1 Financial Overview
  109.       5.2.6.2 Products Offered
  110.       5.2.6.3 Key Developments
  111.       5.2.6.4 SWOT Analysis
  112.       5.2.6.5 Key Strategies
  113.     5.2.7 GSK (GB)
  114.       5.2.7.1 Financial Overview
  115.       5.2.7.2 Products Offered
  116.       5.2.7.3 Key Developments
  117.       5.2.7.4 SWOT Analysis
  118.       5.2.7.5 Key Strategies
  119.     5.2.8 Horizon Therapeutics (IE)
  120.       5.2.8.1 Financial Overview
  121.       5.2.8.2 Products Offered
  122.       5.2.8.3 Key Developments
  123.       5.2.8.4 SWOT Analysis
  124.       5.2.8.5 Key Strategies
  125.     5.2.9 Teva Pharmaceutical Industries (IL)
  126.       5.2.9.1 Financial Overview
  127.       5.2.9.2 Products Offered
  128.       5.2.9.3 Key Developments
  129.       5.2.9.4 SWOT Analysis
  130.       5.2.9.5 Key Strategies
  131.   5.3 Appendix
  132.     5.3.1 References
  133.     5.3.2 Related Reports
  134. 6 LIST OF FIGURES
  135.   6.1 MARKET SYNOPSIS
  136.   6.2 US MARKET ANALYSIS BY TYPE
  137.   6.3 US MARKET ANALYSIS BY THERAPY TYPE
  138.   6.4 US MARKET ANALYSIS BY END-USER
  139.   6.5 KEY BUYING CRITERIA OF MEDICAL DEVICE
  140.   6.6 RESEARCH PROCESS OF MRFR
  141.   6.7 DRO ANALYSIS OF MEDICAL DEVICE
  142.   6.8 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
  143.   6.9 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
  144.   6.10 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
  145.   6.11 MEDICAL DEVICE, BY TYPE, 2024 (% SHARE)
  146.   6.12 MEDICAL DEVICE, BY TYPE, 2024 TO 2035 (USD Million)
  147.   6.13 MEDICAL DEVICE, BY THERAPY TYPE, 2024 (% SHARE)
  148.   6.14 MEDICAL DEVICE, BY THERAPY TYPE, 2024 TO 2035 (USD Million)
  149.   6.15 MEDICAL DEVICE, BY END-USER, 2024 (% SHARE)
  150.   6.16 MEDICAL DEVICE, BY END-USER, 2024 TO 2035 (USD Million)
  151.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  152. 7 LIST OF TABLES
  153.   7.1 LIST OF ASSUMPTIONS
  154.     7.1.1
  155.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  156.     7.2.1 BY TYPE, 2025-2035 (USD Million)
  157.     7.2.2 BY THERAPY TYPE, 2025-2035 (USD Million)
  158.     7.2.3 BY END-USER, 2025-2035 (USD Million)
  159.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  160.     7.3.1
  161.   7.4 ACQUISITION/PARTNERSHIP
  162.     7.4.1

US Medical Device Market Segmentation

Medical Device By Type (USD Million, 2025-2035)

  • sickle cell anemia
  • plastic anemia
  • iron-deficiency anemia

Medical Device By therapy type (USD Million, 2025-2035)

  • Oral Iron Therapy
  • Red Blood Cell Transfusion
  • Parental Iron Therapy
  • Other Therapy Types

Medical Device By end-user (USD Million, 2025-2035)

  • Clinic
  • Healthcare
  • Home healthcare

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓